Search
RenovoRx Inc
RNXTAdd to Watchlist
0.820USD
-0.035-4.09%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
36.94MMarket Cap
LossP/E TTM
More Details of RenovoRx Inc Company
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
RenovoRx Inc Info
Ticker SymbolRNXT
Company nameRenovoRx Inc
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Number of employees10
Security typeOrdinary Share
Fiscal year-endAug 17
Address2570 W. El Camino Real, Ste. 320,
CityMOUNTAIN VIEW
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94040
Phone14088002649
Websitehttps://renovorx.com/
Ticker SymbolRNXT
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Company Executives of RenovoRx Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
6.75%
Vanguard Capital Management, LLC
3.21%
Agah (Ramtin M.D.)
2.66%
Worth Venture Partners, LLC
1.54%
Bleichroeder LP
1.33%
Other
84.51%
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
6.75%
Vanguard Capital Management, LLC
3.21%
Agah (Ramtin M.D.)
2.66%
Worth Venture Partners, LLC
1.54%
Bleichroeder LP
1.33%
Other
84.51%
Shareholder Types
Shareholders
Proportion
Private Equity
6.75%
Investment Advisor
6.40%
Individual Investor
3.77%
Investment Advisor/Hedge Fund
2.51%
Hedge Fund
0.44%
Bank and Trust
0.22%
Family Office
0.14%
Venture Capital
0.11%
Research Firm
0.03%
Other
79.63%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
54
9.02M
20.02%
-632.53K
2025Q4
46
7.35M
20.06%
-2.71M
2025Q3
47
8.06M
22.01%
-3.57M
2025Q2
51
11.72M
32.06%
+5.26M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AIGH Capital Management, LLC.
2.14M
4.75%
+218.70K
+11.37%
Dec 31, 2025
Agah (Ramtin M.D.)
1.20M
2.66%
+10.00K
+0.84%
Jan 21, 2026
Worth Venture Partners, LLC
691.76K
1.54%
--
--
Dec 31, 2025
Bleichroeder LP
600.00K
1.33%
+61.38K
+11.40%
Dec 31, 2025
Geode Capital Management, L.L.C.
371.39K
0.82%
-91.00
-0.02%
Dec 31, 2025
Bagai (Shaun R.)
340.04K
0.75%
+10.00K
+3.03%
Dec 18, 2025
Wealthspire Advisors LLC
252.53K
0.56%
+252.53K
--
Dec 31, 2025
Renaissance Technologies LLC
117.46K
0.26%
-196.09K
-62.54%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
